中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 国家新药筛选中心
Effect of a hepatitis B virus inhibitor, NZ-4, on capsid formation

文献类型：期刊论文

作者Yang, Li1; Wang, Ya-Juan1; Chen, Hai Jun2; Shi, Li-Ping1; Tong, Xian-Kun1; Zhang, Yang-Ming2; Wang, Gui-Feng1; Wang, Wen-Long2; Feng, Chun-Lan1; He, Pei-Lan1
刊名ANTIVIRAL RESEARCH
出版日期2016-01
卷号125页码:25-33
关键词Anti-hepatitis B virus compound Capsid formation pgRNA packaging Arg-rich domain I Faster-migrating capsid
ISSN号0166-3542
DOI10.1016/j.antiviral.2015.11.004
文献子类Article
英文摘要During the hepatitis B virus (HBV) life cycle, nucleocapsid assembly is essential for HBV replication. Both RNA reverse transcription and DNA replication occur within the HBV nucleocapsid. HBV nucleocapsid is consisted of core protein (HBcAg), whose carboxy-terminal domain (CTD) contains an Arg-rich domain (ARD). The ARD of HBcAg does contribute to the encapsidation of pregenomic RNA (pgRNA). Previously, we reported a small-molecule, NZ-4, which dramatically reduced the HBV DNA level in an in vitro cell setting. Here, we explore the possible mechanisms by which NZ-4 inhibits HBV function. As an HBV inhibitor, NZ-4 leads to the formation of genome-free capsids, including a new population of capsid that runs faster on agarose gels. NZ-4's activity was dependent on the presence of the ARD I, containing at least one positively charged amino acid. NZ-4 might provide a new option for further development of HBV therapeutics for the treatment of chronic hepatitis B. (C) 2015 Published by Elsevier B.V.
WOS关键词ARGININE-RICH DOMAIN ; CORE PROTEIN ; REVERSE-TRANSCRIPTASE ; RNA ENCAPSIDATION ; LIFE-CYCLE ; WILD-TYPE ; REPLICATION ; PARTICLES ; HBV ; PHOSPHORYLATION
资助项目Chinese Academy of Sciences (CAS)[KSCX1-YW-10-03] ; National 863 Program Fund[2008AA02Z431] ; National Science & Technology Major Project "Key New Drug Creation and 402 Manufacturing Program"[2009ZX09102-024] ; National Science & Technology Major Project "Key New Drug Creation and 402 Manufacturing Program"[2012ZX09101-113]
WOS研究方向Pharmacology & Pharmacy ; Virology
语种英语
WOS记录号WOS:000369203900004
出版者ELSEVIER SCIENCE BV
源URL[http://119.78.100.183/handle/2S10ELR8/276249]  
专题国家新药筛选中心
中科院受体结构与功能重点实验室
新药研究国家重点实验室
药理学第一研究室
通讯作者Nan, Fa-Jun; Zuo, Jian-Ping
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Lab Immunopharmacol, Shanghai 201203, Peoples R China;
2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Chinese Natl Ctr Drug Screening, Shanghai 201203, Peoples R China;
3.Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China
推荐引用方式
GB/T 7714		 Yang, Li,Wang, Ya-Juan,Chen, Hai Jun,et al. Effect of a hepatitis B virus inhibitor, NZ-4, on capsid formation[J]. ANTIVIRAL RESEARCH,2016,125:25-33.
APA Yang, Li.,Wang, Ya-Juan.,Chen, Hai Jun.,Shi, Li-Ping.,Tong, Xian-Kun.,...&Zuo, Jian-Ping.(2016).Effect of a hepatitis B virus inhibitor, NZ-4, on capsid formation.ANTIVIRAL RESEARCH,125,25-33.
MLA Yang, Li,et al."Effect of a hepatitis B virus inhibitor, NZ-4, on capsid formation".ANTIVIRAL RESEARCH 125(2016):25-33.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。